Mechanism of Chuanxiong Rhizoma-Paeoniae Radix Rubra drug pair on intervention of cerebral ischemia based on network pharmacology-molecular docking.
10.19540/j.cnki.cjcmm.20210225.401
- Author:
Hao-Yan ZHOU
1
;
Ruo-Lan SUN
2
;
Qian-Hui JI
2
;
De-Cai TANG
2
;
Jun-Fei GU
3
Author Information
1. School of Pharmacy, Nanjing University of Chinese Medicine Nanjing 210023, China.
2. School of Traditional Chinese Medicine and School of Integrated Chinese and Western Medicine,Nanjing University of Chinese Medicine Nanjing 210023, China.
3. School of Pharmacy, Nanjing University of Chinese Medicine Nanjing 210023, China School of Traditional Chinese Medicine and School of Integrated Chinese and Western Medicine,Nanjing University of Chinese Medicine Nanjing 210023, China.
- Publication Type:Journal Article
- Keywords:
Chuanxiong Rhizoma;
Paeoniae Radix Rubra;
cerebral ischemia;
drug pair;
molecular docking;
network pharmacology
- MeSH:
Animals;
Brain Ischemia/genetics*;
Cerebral Infarction;
Drugs, Chinese Herbal;
Molecular Docking Simulation;
Paeonia;
Rats;
Rhizome
- From:
China Journal of Chinese Materia Medica
2021;46(12):3007-3015
- CountryChina
- Language:Chinese
-
Abstract:
Cerebral ischemia is one of the most common diseases in China, and the drug pair of Chuanxiong Rhizoma and Paeoniae Radix Rubra can intervene in cerebral ischemia to reduce the inflammatory response of cerebral ischemia and apoptosis. To reveal the intervention mechanism of Chuanxiong Rhizoma-Paeoniae Radix Rubra drug pair on cerebral ischemia systematically, computer network pharmacology technology was used in this paper to predict the target and signaling pathway of the drug pair on the intervention of cerebral ischemia, and then the molecular docking technology was used to further analyze the mechanism of the intervention. The target results were then verified by the rat cerebral ischemia model. The target network results showed that the active compounds of Chuanxiong Rhizoma-Paeoniae Radix Rubra for cerebral ischemic disease contained 30 compounds, 38 targets and 9 pathways. The main compounds included phenolic acids in Chuanxiong Rhizoma and monoterpene glycosides in Paeoniae Radix Rubra. The key targets involved mitogen-activated protein kinase 1(MAPK1), steroid receptor coactivator(SRC), epidermal growth factor receptor(EGFR), mitogen-activated protein kinase 14(MAPK14), caspase-3(CASP3), caspase-7(CASP7), estrogen receptor 1(ESR1), and mitogen-activated protein kinase 8(MAPK8), etc. The target gene functions were biased towards protein kinase activity, protein autophosphorylation, peptidyl-serine phosphorylation and protein serine/threonine kinase activity, etc. The important KEGG pathways involved Ras signaling pathway, ErbB signaling pathway and VEGF signaling pathway. Molecular docking results showed that catechin, oxypaeoniflorin, albiflorin, paeoniflorin and benzoylpaeoniflorin had strong binding ability with MAPK1, SRC, EGFR, MAPK14 and CASP7. MCAO rat experimental results showed that Chuanxiong Rhizoma-Paeoniae Radix Rubra significantly improved the cerebral ischemia injury and interstitial edema, and significantly reduced the activation of caspase-7 and the phosphorylation of ERK1/2. The Chuanxiong Rhizoma-Paeoniae Radix Rubra drug pair alleviated cerebral ischemia injury through a network model of multi-phenotype intervention by promoting cell proliferation and differentiation, reducing inflammatory factor expression, protecting nerve cells from death and figh-ting against neuronal cell apoptosis, with its action signaling pathway most related to Ras signaling pathway, ErbB signaling pathway and VEGF signaling pathway. This study provides the basis for clinical intervention of Chuanxiong Rhizoma-Paeoniae Radix Rubra drug pair on cerebral ischemia, and also provides ideas for the modernization of drug pairs.
